ReviewWorld journal of gastroenterology2026
Research progress of plant-derived chemical compounds for overcoming pancreatic cancer drug resistance.
Review in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer, a highly malignant gastrointestinal tumor, has a five-year survival rate of only 10%. With the increasing aging population, its incidence is rising across East Asia, North America, and Europe. Chemotherapy remains a basic strategy of the current treatment regimen for pancreatic cancer. However, the development of multidrug resistance poses a significant challenge, drastically reducing the efficacy of chemotherapy agents. The mechanisms underlying resistance in pancreatic cancer remain incompletely understood. To overcome this obstacle, scientists are dedicated to discovering new therapeutic strategies and addressing the issue of resistance. Plant-derived chemicals played essential roles in many documented ancient cultures, such as those in ancient China, ancient Egypt, ancient India, and ancient Babylon. Many modern medications are derived from plants, including paclitaxel, a widely used and effective chemotherapy agent originally derived from the Pacific yew tree. Although the development of plant-based compounds for cancer treatment is still under development, these compounds offer several advantages, including a long history of safe use, fewer side effects, lower costs, and improved patient acceptance. Recent studies have shown that plant-derived chemicals can significantly inhibit tumor cell proliferation and reversal drug resistance. Clinical trials have demonstrated promising therapeutic effects of these compounds in cancer treatment. This review summarizes recent research on the role of plant-derived compounds in overcoming drug resistance in pancreatic cancer. It provides insights into the mechanisms of drug resistance and highlights the potential of plant-based compounds as alternative therapeutic strategies. Considering the limitations of current therapies and the growing issue of drug resistance, plant-derived compounds offer a promising direction for enhancing treatment outcomes. This review aims to inform future research and promote the development of more effective, safer, and patient-friendly treatment options for pancreatic cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.